CoChat
Sign Up
Cited by 21Virus-based gene therapy researchHIV Research and TreatmentHIV/AIDS drug development and treatment

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Development of Lentiviral Vectors for HIV-1 Gene Therapy with Vif-Resistant APOBEC3G

Open access
Delviks-Frankenberry, Krista A., Ackerman, Daniel, Timberlake, Nina D., Hamscher, Maria, Nikolaitchik, Olga A., Hu, Wei-Shau, Torbett, Bruce E., Pathak, Vinay K.·2019·Molecular Therapy Nucleic Acids
DOI 10.1016/j.omtn.2019.10.024PMC PMC6889484
Open this paper in CoChat — free account

Abstract

Strategies to control HIV-1 replication without antiviral therapy are needed to achieve a functional cure. To exploit the innate antiviral function of restriction factor cytidine deaminase APOBEC3G ( A3G ), we developed self-activating lentiviral vectors that efficiently deliver HIV-1 Vif-resistant mutant A3G-D128K to target cells. To circumvent APOBEC3 expression in virus-producing cells, which diminishes virus infectivity, a vector containing two overlapping fragments of A3G-D128K was designed that maintained the gene in an inactive form in the virus-producer cells. However, during transduction of target cells, retroviral recombination between the direct repeats reconstituted an active A3G-D128K in 89%–98% of transduced cells. Lentiviral vectors that expressed A3G-D128K transduced CD34 + hematopoietic stem and progenitor cells with a high efficiency (>30%). A3G-D128K expression in T cell lines CEM, CEMSS, and PM1 potently inhibited spreading infection of several HIV-1 subtypes by C-to-U deamination leading to lethal G-to-A hypermutation and inhibition of reverse transcription. SIVmac239 and HIV-2 were not inhibited, since their Vifs degraded A3G-D128K. A3G-D128K expression in CEM cells potently suppressed HIV-1 replication for >3.5 months without detectable resistant virus, suggesting a high genetic barrier for the emergence of A3G-D128K resistance. Because of this, A3G-D128K expression in HIV-1 target cells is a potential anti-HIV gene therapy approach that could be combined with other therapies for the treatment and functional cure of HIV-1 infection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omtn.2019.10.024

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • HIV-1 derived lentiviral vectors are well known for efficient and stable transduction in dividing and non-dividing cells.

    “HIV-1 derived LV is well known for its efficient and stable transduction in dividing and non-dividing cells.”

    From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [1]

    The Results section on CD4+ T cells and CD34+ HSPCs (page unavailable) reports efficient transduction with the studied lentiviral vector. The Materials and Methods section describes expanded, selected transduced cell pools, consistent with sustained expression in those cells. Our copy does not establish efficient, stable transduction in non-dividing cells, so the broader claim is only partly supported. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 96

  1. Cihlar, 2016, Current status and prospects of HIV treatment, Curr. Opin. Virol., 18, 50, 10.1016/j.coviro.2016.03.004 · DOI
  2. Wang, 2016, Engineering hematopoietic stem cells toward a functional cure of human immunodeficiency virus infection, Cytotherapy, 18, 1370, 10.1016/j.jcyt.2016.07.007 · DOI
  3. Gupta, 2019, HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation, Nature, 568, 244, 10.1038/s41586-019-1027-4 · DOI
  4. Hütter, 2009, Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation, N. Engl. J. Med., 360, 692, 10.1056/NEJMoa0802905 · DOI
  5. Luzuriaga, 2015, Viremic relapse after HIV-1 remission in a perinatally infected child, N. Engl. J. Med., 372, 786, 10.1056/NEJMc1413931 · DOI
  6. Persaud, 2013, Absence of detectable HIV-1 viremia after treatment cessation in an infant, N. Engl. J. Med., 369, 1828, 10.1056/NEJMoa1302976 · DOI
  7. Henrich, 2014, Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases, Ann. Intern. Med., 161, 319, 10.7326/M14-1027 · DOI
  8. Kordelas, 2014, Shift of HIV tropism in stem-cell transplantation with CCR5 delta32 mutation, N. Engl. J. Med., 371, 880, 10.1056/NEJMc1405805 · DOI
  9. Sheehy, 2002, Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein, Nature, 418, 646, 10.1038/nature00939 · DOI
  10. Stremlau, 2004, The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys, Nature, 427, 848, 10.1038/nature02343 · DOI
  11. Sayah, 2004, Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1, Nature, 430, 569, 10.1038/nature02777 · DOI · Paper page
  12. Jouvenet, 2009, Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin, J. Virol., 83, 1837, 10.1128/JVI.02211-08 · DOI
  13. Neil, 2008, Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu, Nature, 451, 425, 10.1038/nature06553 · DOI
  14. Goujon, 2013, Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection, Nature, 502, 559, 10.1038/nature12542 · DOI
  15. Kane, 2013, MX2 is an interferon-induced inhibitor of HIV-1 infection, Nature, 502, 563, 10.1038/nature12653 · DOI
  16. Schoggins, 2011, A diverse range of gene products are effectors of the type I interferon antiviral response, Nature, 472, 481, 10.1038/nature09907 · DOI
  17. Lecossier, 2003, Hypermutation of HIV-1 DNA in the absence of the Vif protein, Science, 300, 1112, 10.1126/science.1083338 · DOI
  18. Harris, 2003, DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses, Nat. Immunol., 4, 641, 10.1038/ni0703-641 · DOI
  19. Desimmie, 2014, Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all, J. Mol. Biol., 426, 1220, 10.1016/j.jmb.2013.10.033 · DOI
  20. Mbisa, 2007, Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration, J. Virol., 81, 7099, 10.1128/JVI.00272-07 · DOI
  21. Pollpeter, 2018, Deep sequencing of HIV-1 reverse transcripts reveals the multifaceted antiviral functions of APOBEC3G, Nat. Microbiol., 3, 220, 10.1038/s41564-017-0063-9 · DOI
  22. Luo, 2007, Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation, J. Virol., 81, 7238, 10.1128/JVI.02584-06 · DOI
  23. Mbisa, 2010, APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms, J. Virol., 84, 5250, 10.1128/JVI.02358-09 · DOI
  24. Smith, 2009, Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development, Trends Pharmacol. Sci., 30, 638, 10.1016/j.tips.2009.09.006 · DOI
  25. Yu, 2003, Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex, Science, 302, 1056, 10.1126/science.1089591 · DOI
  26. Li, 2008, APOBEC3G-UBA2 fusion as a potential strategy for stable expression of APOBEC3G and inhibition of HIV-1 replication, Retrovirology, 5, 72, 10.1186/1742-4690-5-72 · DOI
  27. Ao, 2011, Characterization of anti-HIV activity mediated by R88-APOBEC3G mutant fusion proteins in CD4+ T cells, peripheral blood mononuclear cells, and macrophages, Hum. Gene Ther., 22, 1225, 10.1089/hum.2010.012 · DOI
  28. Green, 2009, Inhibition of HIV-1 infection and replication by enhancing viral incorporation of innate anti-HIV-1 protein A3G: a non-pathogenic Nef mutant-based anti-HIV strategy, J. Biol. Chem., 284, 13363, 10.1074/jbc.M806631200 · DOI
  29. Sakuma, 2007, Inhibition of HIV-1 replication by simian restriction factors, TRIM5alpha and APOBEC3G, Gene Ther., 14, 185, 10.1038/sj.gt.3302852 · DOI
  30. Wang, 2014, R88-APOBEC3Gm inhibits the replication of both drug-resistant strains of HIV-1 and viruses produced from latently infected cells, Mol. Ther. Nucleic Acids, 3, e151, 10.1038/mtna.2014.2 · DOI
  31. Ao, 2008, Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection, PLoS ONE, 3, e1995, 10.1371/journal.pone.0001995 · DOI
  32. Voit, 2013, Generation of an HIV resistant T-cell line by targeted “stacking” of restriction factors, Mol. Ther., 21, 786, 10.1038/mt.2012.284 · DOI · Paper page
  33. Delviks-Frankenberry, 2011, Mechanisms and factors that influence high frequency retroviral recombination, Viruses, 3, 1650, 10.3390/v3091650 · DOI
  34. Hu, 2000, Design of retroviral vectors and helper cells for gene therapy, Pharmacol. Rev., 52, 493, 10.1016/S0031-6997(24)01467-4 · DOI
  35. Hwang, 2001, Dynamic copy choice: steady state between murine leukemia virus polymerase and polymerase-dependent RNase H activity determines frequency of in vivo template switching, Proc. Natl. Acad. Sci. USA, 98, 12209, 10.1073/pnas.221289898 · DOI
  36. An, 2001, Frequency of direct repeat deletion in a human immunodeficiency virus type 1 vector during reverse transcription in human cells, Virology, 286, 475, 10.1006/viro.2001.1025 · DOI
  37. Delviks, 1997, Psi- vectors: murine leukemia virus-based self-inactivating and self-activating retroviral vectors, J. Virol., 71, 6218, 10.1128/jvi.71.8.6218-6224.1997 · DOI
  38. Delviks, 1999, Development of murine leukemia virus-based self-activating vectors that efficiently delete the selectable drug resistance gene during reverse transcription, J. Virol., 73, 8837, 10.1128/JVI.73.10.8837-8842.1999 · DOI
  39. Delviks, 1999, Effect of distance between homologous sequences and 3′ homology on the frequency of retroviral reverse transcriptase template switching, J. Virol., 73, 7923, 10.1128/JVI.73.10.7923-7932.1999 · DOI
  40. Nikolenko, 2004, Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency, J. Virol., 78, 8761, 10.1128/JVI.78.16.8761-8770.2004 · DOI
  41. Pathak, 1990, Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations, Proc. Natl. Acad. Sci. USA, 87, 6019, 10.1073/pnas.87.16.6019 · DOI
  42. Kim, 2011, High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice, PLoS ONE, 6, e18556, 10.1371/journal.pone.0018556 · DOI
  43. Xu, 2004, A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion, Proc. Natl. Acad. Sci. USA, 101, 5652, 10.1073/pnas.0400830101 · DOI
  44. Browne, 2009, Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent, Virology, 387, 313, 10.1016/j.virol.2009.02.026 · DOI
  45. Chaipan, 2013, APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages, J. Virol., 87, 444, 10.1128/JVI.00676-12 · DOI
  46. Han, 2008, APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication, PLoS Pathog., 4, e1000095, 10.1371/journal.ppat.1000095 · DOI
  47. Brown, 2005, Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines, J. Virol., 79, 6089, 10.1128/JVI.79.10.6089-6101.2005 · DOI
  48. Schröfelbauer, 2006, Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G, J. Virol., 80, 5984, 10.1128/JVI.00388-06 · DOI
  49. Russell, 2007, Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F, J. Virol., 81, 8201, 10.1128/JVI.00395-07 · DOI
  50. Schröfelbauer, 2004, A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif), Proc. Natl. Acad. Sci. USA, 101, 3927, 10.1073/pnas.0307132101 · DOI
  51. Haworth, 2017, CCR5-edited gene therapies for HIV cure: closing the door to viral entry, Cytotherapy, 19, 1325, 10.1016/j.jcyt.2017.05.013 · DOI
  52. Verheyen, 2014, More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32/delta32 mutation, N. Engl. J. Med., 371, 2438
  53. Younan, 2013, Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model, Blood, 122, 179, 10.1182/blood-2013-01-482224 · DOI
  54. Kuhlmann, 2018, Chimeric antigen receptor T-cell approaches to HIV cure, Curr. Opin. HIV AIDS, 13, 446, 10.1097/COH.0000000000000485 · DOI
  55. Koujah, 2019, CRISPR-Cas based targeting of host and viral genes as an antiviral strategy, Semin. Cell Dev. Biol., 10.1016/j.semcdb.2019.04.004 · DOI
  56. Xiao, 2019, Application of CRISPR/Cas9-based gene editing in HIV-1/AIDS therapy, Front. Cell. Infect. Microbiol., 9, 69, 10.3389/fcimb.2019.00069 · DOI
  57. Colomer-Lluch, 2018, Restriction factors: from intrinsic viral restriction to shaping cellular immunity against HIV-1, Front. Immunol., 9, 2876, 10.3389/fimmu.2018.02876 · DOI
  58. Rogers, 2017, Gene therapy approaches to human immunodeficiency virus and other infectious diseases, Hematol. Oncol. Clin. North Am., 31, 883, 10.1016/j.hoc.2017.06.008 · DOI
  59. Sloan, 2013, Harnessing the therapeutic potential of host antiviral restriction factors that target HIV, Expert Rev. Anti Infect. Ther., 11, 1, 10.1586/eri.12.146 · DOI
  60. Delviks-Frankenberry, 2016, Minimal contribution of APOBEC3-induced G-to-A hypermutation to HIV-1 recombination and genetic variation, PLoS Pathog., 12, e1005646, 10.1371/journal.ppat.1005646 · DOI
  61. Kim, 1996, Retroviral mutation rates and A-to-G hypermutations during different stages of retroviral replication, J. Virol., 70, 7594, 10.1128/jvi.70.11.7594-7602.1996 · DOI
  62. Mansky, 1994, Lower mutation rate of bovine leukemia virus relative to that of spleen necrosis virus, J. Virol., 68, 494, 10.1128/jvi.68.1.494-499.1994 · DOI
  63. Hosseini, 2012, Multi-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapy, PLoS Comput. Biol., 8, e1002371, 10.1371/journal.pcbi.1002371 · DOI
  64. Haché, 2009, Optimal translation initiation enables Vif-deficient human immunodeficiency virus type 1 to escape restriction by APOBEC3G, J. Virol., 83, 5956, 10.1128/JVI.00045-09 · DOI
  65. Ikeda, 2018, HIV-1 adaptation studies reveal a novel Env-mediated homeostasis mechanism for evading lethal hypermutation by APOBEC3G, PLoS Pathog., 14, e1007010, 10.1371/journal.ppat.1007010 · DOI
  66. Miyagi, 2017, Long-term passage of Vif-null HIV-1 in CD4+ T cells expressing sub-lethal levels of APOBEC proteins fails to develop APOBEC resistance, Virology, 504, 1, 10.1016/j.virol.2017.01.016 · DOI
  67. Russell, 2009, Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif, J. Virol., 83, 1992, 10.1128/JVI.01621-08 · DOI
  68. Yamashita, 2008, Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F, Microbes Infect., 10, 1142, 10.1016/j.micinf.2008.06.003 · DOI
  69. Kikuchi, 2015, Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers, J. Virol., 89, 4992, 10.1128/JVI.03464-14 · DOI
  70. De Pasquale, 2013, Lower HIV provirus levels are associated with more APOBEC3G protein in blood resting memory CD4+ T lymphocytes of controllers in vivo, PLoS ONE, 8, e76002, 10.1371/journal.pone.0076002 · DOI
  71. Kourteva, 2012, APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo, Virology, 430, 1, 10.1016/j.virol.2012.03.018 · DOI
  72. Delville, 2018, A nontoxic transduction enhancer enables highly efficient lentiviral transduction of primary murine T cells and hematopoietic stem cells, Mol. Ther. Methods Clin. Dev., 10, 341, 10.1016/j.omtm.2018.08.002 · DOI
  73. Mochizuki, 1998, High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells, J. Virol., 72, 8873, 10.1128/JVI.72.11.8873-8883.1998 · DOI
  74. Yee, 1994, A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes, Proc. Natl. Acad. Sci. USA, 91, 9564, 10.1073/pnas.91.20.9564 · DOI
  75. Smith, 2014, HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants, J. Virol., 88, 9893, 10.1128/JVI.01318-14 · DOI
  76. Nikolenko, 2007, Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance, Proc. Natl. Acad. Sci. USA, 104, 317, 10.1073/pnas.0609642104 · DOI
  77. Adachi, 1986, Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone, J. Virol., 59, 284, 10.1128/jvi.59.2.284-291.1986 · DOI
  78. Ndung’u, 2001, Construction and analysis of an infectious human Immunodeficiency virus type 1 subtype C molecular clone, J. Virol., 75, 4964, 10.1128/JVI.75.11.4964-4972.2001 · DOI
  79. Gao, 1996, The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin, J. Virol., 70, 7013, 10.1128/jvi.70.10.7013-7029.1996 · DOI
  80. Regier, 1990, The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus, AIDS Res. Hum. Retroviruses, 6, 1221, 10.1089/aid.1990.6.1221 · DOI
  81. Gallo, 1984, Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS, Science, 224, 500, 10.1126/science.6200936 · DOI
  82. Michael, 1999, Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes, J. Clin. Microbiol., 37, 2557, 10.1128/JCM.37.8.2557-2563.1999 · DOI
  83. Virgen, 2007, Antiretroviral activity and Vif sensitivity of rhesus macaque APOBEC3 proteins, J. Virol., 81, 13932, 10.1128/JVI.01760-07 · DOI
  84. Salter, 1985, Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids, Immunogenetics, 21, 235, 10.1007/BF00375376 · DOI
  85. Lusso, 1995, Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1, J. Virol., 69, 3712, 10.1128/jvi.69.6.3712-3720.1995 · DOI
  86. Foley, 1965, Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia, Cancer, 18, 522, 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J · DOI
  87. Derdeyn, 2000, Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120, J. Virol., 74, 8358, 10.1128/JVI.74.18.8358-8367.2000 · DOI
  88. Wei, 2002, Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy, Antimicrob. Agents Chemother., 46, 1896, 10.1128/AAC.46.6.1896-1905.2002 · DOI · Paper page
  89. Wang, 2014, Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells, Blood, 124, 913, 10.1182/blood-2013-12-546218 · DOI
  90. Kao, 2004, Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells, Retrovirology, 1, 27, 10.1186/1742-4690-1-27 · DOI
  91. Khan, 2005, Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes, J. Virol., 79, 5870, 10.1128/JVI.79.9.5870-5874.2005 · DOI
  92. Holmes, 2007, APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G, J. Biol. Chem., 282, 2587, 10.1074/jbc.M607298200 · DOI
  93. Simon, 1997, The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells, J. Virol., 71, 5259, 10.1128/jvi.71.7.5259-5267.1997 · DOI
  94. Deng, 1997, Expression cloning of new receptors used by simian and human immunodeficiency viruses, Nature, 388, 296, 10.1038/40894 · DOI
  95. Pöhlmann, 1999, Coreceptor usage of BOB/GPR15 and Bonzo/STRL33 by primary isolates of human immunodeficiency virus type 1, J. Gen. Virol., 80, 1241, 10.1099/0022-1317-80-5-1241 · DOI
  96. Ozog, 2018, CD46 null packaging cell line improves measles lentiviral vector production and gene delivery to hematopoietic stem and progenitor cells, Mol. Ther. Methods Clin. Dev., 13, 27, 10.1016/j.omtm.2018.11.006 · DOI

Cited by

Sorted by citations

Metadata

Authors
Delviks-Frankenberry, K. A., Ackerman, D., Timberlake, N. D., Hamscher, M., Nikolaitchik, O. A., Hu, W.-S., Torbett, B. E., & Pathak, V. K.
Affiliations
  • National Cancer Institute (US)
  • Scripps Research Institute (US)
  • Frederick National Laboratory for Cancer Research (US)
Corresponding author
Pathak, Vinay K.
ORCID
Venue
Molecular Therapy Nucleic Acids
Publisher
Elsevier BV
Published
2019-12
Volume
18
Pages
1023-1038
ISSN
2162-2531 (ISSN-L)
DOI
10.1016/j.omtn.2019.10.024
PMC
PMC6889484
OpenAlex
W2989435356
Cited by
21
References
2
Citations by year
2026: 1 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 1 · 2020: 4
FWCI
1.66
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Therapy — Nucleic Acids (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Department of Health, Australian Government
  • National Institutes of Health
  • National Cancer Institute
  • Office of AIDS Research (5T32AI007354, P30 AI036214, R01HL116221, U54GM103368)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Keywords
HIV-1 gene therapy, lentiviral vectors, APOBEC3G, host restriction factors, G-to-A hypermutation, reverse transcription inhibition, retroviral recombination, direct repeats, hematopoietic stem and progenitor cells, T cell lines, HIV-1 replication inhibition, functional cure, HIV-2, SIVmac239

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review